Author:
Orentas Rimas J.,Sindiri Sivasish,Duris Christine,Wen Xinyu,He Jianbin,Wei Jun S.,Jarzembowski Jason,Khan Javed
Reference76 articles.
1. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE® antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications;Hoffman;Front Oncol,2014
2. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study;Topp;Lancet Oncol,2015
3. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies;Robak;Curr Opin Investig Drugs,2009
4. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor;Kochenderfer;J Clin Oncol,2015
5. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N Engl J Med,2011
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献